ZG006 injection versus chemotherapy for advanced neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether a new drug called ZG006 works better than standard chemotherapy for advanced neuroendocrine carcinoma (a rare cancer that starts in hormone-producing cells). You'll be randomly assigned to receive either ZG006 or a chemotherapy your doctor chooses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have advanced neuroendocrine carcinoma confirmed by biopsy or cell sample
- You do not have small cell lung cancer (SCLC) or a combined SCLC
- You are willing to provide written consent and participate fully
- If your cancer is DLL3-positive, you may have had prior treatment but cannot have had more than one prior chemotherapy line
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This trial tests a new drug (ZG005) combined with two standard chemotherapy drugs (etoposide and cisplatin) for people with advanced neuroendocrine carcinoma that has spread or come back. The goal is to see if the combination works better than the standard treatment alone.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.